IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

31 8 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

27 8 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 8 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 7 2021 08:00:03 提供 Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 7 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 6 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 6 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reveals a New Anti-LAG-3 Research Program

08 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 08:00:00 提供 Nasdaq GlobeNewswire